Project Grant K01CA303796
Award Date
8/1/25
Completion Date
7/31/30
Dollars Obligated
$183K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
This National Cancer Institute (NCI) Project Grant award under the Cancer Biology Research program (CFDA 93.396) provides $456,103 in funding to The Feinstein Institutes for Medical Research to develop integrated risk models for endometrial cancer. The project aims to enhance early detection of endometrial cancer by determining the burden of rare genetic risk factors and creating predictive models that integrate genetic and non-genetic factors such as BMI, diabetes, and PCOS. The research will...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $132,825 to the Sloan-Kettering Institute for Cancer Research to develop and validate prognostic models for Black women with endometrial cancer following hysterectomy. The specific aims are to: 1) build and externally validate a prognostic tool for Black endometrial cancer patients using clinical and epidemiological factors, 2) assess the utility of adding molecular...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $159,803 to the Regents of the University of Michigan to incorporate emerging genomic, transcriptomic, epigenomic, and proteomic technologies for the analysis of advanced, rare, and pediatric cancers. The project aims to translate these new analytical approaches into clinically actionable information through the development of reportable test results in the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $447,340 to the University of Miami to support research aimed at identifying epigenetic vulnerabilities in endocrine-resistant breast cancer. The project will investigate the role of the CoREST-SWI/SNF axis in regulating breast cancer cell plasticity and endocrine therapy resistance, focusing on two key resistant settings: breast cancers with ESR1 mutations and those with ARID1A...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research federal grant program (CFDA 93.395), provides $113,202 to support research capacity building efforts by Dr. Elie Dib at the Michigan Cancer Research Consortium (MCRC). The key products and services to be delivered through this award include: Contributing to MCRC initiatives aimed at increasing the rate of clinical trials enrollment by minority and underserved populations. Launching safety...
This federal Project Grant award of $334,233, awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, will support a comprehensive research study examining disparities in novel cancer therapies, the joint effects of cancer treatment and comorbidities, and multi-level contributors to cancer survival outcomes. The University of South Carolina, the prime awardee, will conduct innovative data linkages between the state cancer registry,...
The National Cancer Institute (NCI) awarded a $512,974 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research, a non-profit cancer research institution located in New York City. The grant, effective August 13, 2024 through July 31, 2029, will fund research to develop advanced predictive models for non-small cell lung cancer (NSCLC) outcomes using a combination of real-world data sources, including tumor genomic...
This $2,372,456 Project Grant awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support a collaborative research program led by Memorial Sloan Kettering Cancer Center focused on leveraging observational (real-world) data to advance precision oncology. The key products and services to be delivered include: Overcoming methodological barriers in the analysis of observational clinico-genomic data (Project 1) Addressing the role of genetic ancestry...
This federal Project Grant award, valued at $352,141, was provided by the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353). The award will fund research at Wayne State University in Detroit, Michigan to identify ancestry-specific genetic regulators of macrophage function and response to anti-HER2 antibody therapy that may underlie racial disparities in outcomes for HER2-positive breast cancer patients. The research aims to...
This Project Grant award of $1,165,096 from the National Cancer Institute under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) will support a research project to investigate the biological mechanisms linking structural racism, perceived discrimination, and breast cancer survival. The primary awardee, the Sloan-Kettering Institute for Cancer Research, will conduct a large-scale social genomics study of 750 diverse breast cancer patients to: 1) define the...